Phase I/II Study Evaluating the Infusion of Tumour-Infiltrating Lymphocytes (TILs) and Low-Dose Interleukin-2 (IL-2) Therapy Following a Preparative Regimen of Non-myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients With Malignant Pleural Mesothelioma
This is a phase I and II clinical study for patients with malignant pleural mesothelioma (a
type of cancer affecting the lining of the lung). Patients will receive an infusion (given
by vein) of autologous tumour infiltrating lymphocytes (TILs). TILs are a type of white blood
cells that recognizes tumour cells and enter them which causes the tumour cells to break down.
Prior to the cell infusion, patients will receive a two drugs cyclophosphamide and
fludarabine to prepare the body to receive the TILs. After cell infusion, patients will
receive low-dose interleukin-2 therapy. This study will see how safe and useful this regimen
is in treating malignant pleural mesothelioma.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society